Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-03-2019 | Lung Cancer | Original Article – Cancer Research

ZWINT is the next potential target for lung cancer therapy

Authors: Fang Peng, Qiang Li, Shao-Qing Niu, Guo-Ping Shen, Ying Luo, Ming Chen, Yong Bao

Published in: Journal of Cancer Research and Clinical Oncology | Issue 3/2019

Abstract

Purpose

We aimed to analyze the expression of ZWINT, NUSAP1, DLGAP5, and PRC1 in tumor tissues and adjacent tissues with public data.

Methods

The expression patterns of four genes were detected in cancer tissues and adjacent tissues by qRT-PCR. The overall survival analysis was used to explore these genes in lung adenocarcinoma and squamous cell carcinoma patients. Knockdown assays were used to select the most suitable gene among these four genes. Cell function assays with the knockdown gene were conducted in A549 and NCL H226 cells. The role of the knockdown gene in lung cancer was dissected in a mice tumor model. Transcriptome sequencing analyses with the knockdown gene were analyzed.

Results

Overexpression of these genes was significantly detected in cancer tissues (P < 0.01). Overall survival revealed that high expression of these genes is closely related with poor prognosis of lung adenocarcinoma patients (P < 0.05). Knockdown of ZWINT reduced proliferation in NCI H226 and A549 cells (P < 0.05). Knockdown also inhibited cell migration, invasion, apoptosis, and colony formation (P < 0.05). ZWINT knockdown reduced tumor volume (P < 0.05). Transcriptome sequencing of ZWINT knockdown-treated A549 and NCI H226 cells indicated that 100 and 426 differentially expressed genes were obtained, respectively. Gene ontology analysis suggested that binding, biological regulation, and multicellular organismal processes were the most enriched. KEGG analysis revealed that TNF, P53, and PI3K signal networks would be the most potential ZWINT-related pathways and were identified by Western blot analysis.

Conclusions

ZWINT may be a novel target for lung cancer therapy.

Available only for authorised users

Bartkova J et al (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434:864–870. https://doi.org/10.1038/nature03482 CrossRefPubMed

Bass AJ et al (2009) SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 41:1238–1242. https://doi.org/10.1038/ng.465 CrossRefPubMedPubMedCentral

Brendle A et al (2009) Single nucleotide polymorphisms in chromosomal instability genes and risk and clinical outcome of breast cancer: a Swedish prospective case–control study. Eur J Cancer 45:435–442. https://doi.org/10.1016/j.ejca.2008.10.001 CrossRefPubMed

Chen L et al (2015a) High levels of nucleolar spindle-associated protein and reduced levels of BRCA1 expression predict poor prognosis in triple-negative breast cancer. PLoS One 10:e0140572. https://doi.org/10.1371/journal.pone.0140572 CrossRefPubMedPubMedCentral

Chen L, Zhuo D, Chen J, Yuan H (2015b) Screening feature genes of lung carcinoma with DNA microarray analysis. Int J Clin Exp Med 8:12161–12171PubMedPubMedCentral

Chou HY, Wang TH, Lee SC, Hsu PH, Tsai MD, Chang CL, Jeng YM (2011) Phosphorylation of NuSAP by Cdk1 regulates its interaction with microtubules in mitosis. Cell Cycle 10:4083–4089. https://doi.org/10.4161/cc.10.23.18200 CrossRefPubMed

Cooper WA, Lam DC, O’Toole SA, Minna JD (2013) Molecular biology of lung cancer. J Thorac Dis 5(Suppl 5):S479–S490 https://doi.org/10.3978/j.issn.2072-1439.2013.08.03 CrossRefPubMedPubMedCentral

de Bruin EC et al (2014) Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346:251–256. https://doi.org/10.1126/science.1253462 CrossRefPubMedPubMedCentral

Ding L et al (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069–1075. https://doi.org/10.1038/nature07423 CrossRefPubMedPubMedCentral

Dolly SO, Collins DC, Sundar R, Popat S, Yap TA (2017) Advances in the development of molecularly targeted agents in non-small-cell lung cancer. Drugs 77:813–827. https://doi.org/10.1007/s40265-017-0732-2 CrossRefPubMed

Engeland K (2018) Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM. Cell Death Differ 25:114–132. https://doi.org/10.1038/cdd.2017.172 CrossRefPubMed

Espinosa AM et al (2013) Mitosis is a source of potential markers for screening and survival and therapeutic targets in cervical cancer. PLoS One 8:e55975. https://doi.org/10.1371/journal.pone.0055975 CrossRefPubMedPubMedCentral

Gomez CR et al (2013) Prognostic value of discs large homolog 7 transcript levels in prostate cancer. PLoS One 8:e82833. https://doi.org/10.1371/journal.pone.0082833 CrossRefPubMedPubMedCentral

Gordon CA, Gong X, Ganesh D, Brooks JD (2017) NUSAP1 promotes invasion and metastasis of prostate cancer. Oncotarget 8:29935–29950. https://doi.org/10.18632/oncotarget.15604 CrossRefPubMedPubMedCentral

Gorgoulis VG et al (2005) Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434:907–913. https://doi.org/10.1038/nature03485 CrossRefPubMed

Hanibuchi M, Kim SJ, Fidler IJ, Nishioka Y (2014) The molecular biology of lung cancer brain metastasis: an overview of current comprehensions and future perspectives. J Med Investig 61:241–253CrossRef

Hassan M, Watari H, AbuAlmaaty A, Ohba Y, Sakuragi N (2014) Apoptosis and molecular targeting therapy in cancer. Biomed Res Int 2014:150845. https://doi.org/10.1155/2014/150845 CrossRefPubMedPubMedCentral

Hata A et al (2013) Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: comparison between T790M mutation-positive and mutation-negative populations. Cancer 119:4325–4332. https://doi.org/10.1002/cncr.28364 CrossRefPubMed

Hu CK, Ozlu N, Coughlin M, Steen JJ, Mitchison TJ (2012) Plk1 negatively regulates PRC1 to prevent premature midzone formation before cytokinesis. Mol Biol Cell 23:2702–2711. https://doi.org/10.1091/mbc.E12-01-0058 CrossRefPubMedPubMedCentral

Huang X, Zhang X, Farahvash B, Olumi AF (2007) Novel targeted pro-apoptotic agents for the treatment of prostate cancer. J Urol 178:1846–1854. https://doi.org/10.1016/j.juro.2007.06.039 CrossRefPubMed

Imielinski M et al (2012) Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150:1107–1120. https://doi.org/10.1016/j.cell.2012.08.029 CrossRefPubMedPubMedCentral

Kanehira M et al (2007) Oncogenic role of MPHOSPH1, a cancer-testis antigen specific to human bladder cancer. Cancer Res 67:3276–3285. https://doi.org/10.1158/0008-5472.can-06-3748 CrossRefPubMed

Kikuchi T et al (2003) Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 22:2192–2205. https://doi.org/10.1038/sj.onc.1206288 CrossRefPubMed

Kops GJ, Weaver BA, Cleveland DW (2005) On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 5:773–785. https://doi.org/10.1038/nrc1714 CrossRefPubMed

Kwak EL et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693–1703. https://doi.org/10.1056/NEJMoa1006448 CrossRefPubMedPubMedCentral

Lin YM, Furukawa Y, Tsunoda T, Yue CT, Yang KC, Nakamura Y (2002) Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas. Oncogene 21:4120–4128. https://doi.org/10.1038/sj.onc.1205518 CrossRefPubMed

Lin KH et al (2018) RNA-seq transcriptome analysis of breast cancer cell lines under shikonin treatment. Sci Rep 8:2672. https://doi.org/10.1038/s41598-018-21065-x CrossRefPubMedPubMedCentral

Luo HW et al (2016) Protein regulator of cytokinesis 1 overexpression predicts biochemical recurrence in men with prostate cancer. Biomed Pharmacother 78:116–120. https://doi.org/10.1016/j.biopha.2016.01.004 CrossRefPubMed

Maemondo M et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N. Engl J Med 362:2380–2388. https://doi.org/10.1056/NEJMoa0909530 CrossRef

McGuire S (2016) World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr 7:418–419. https://doi.org/10.3945/an.116.012211 CrossRefPubMedPubMedCentral

Nakamura T et al (2004) Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. Oncogene 23:2385–2400. https://doi.org/10.1038/sj.onc.1207392 CrossRefPubMed

Obama K, Ura K, Satoh S, Nakamura Y, Furukawa Y (2005) Up-regulation of PSF2, a member of the GINS multiprotein complex in intrahepatic cholangiocarcinoma. Oncol Rep 14:701–706PubMed

Pao W et al (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306–13311. https://doi.org/10.1073/pnas.0405220101 CrossRefPubMedPubMedCentral

Ramalingam SS, Owonikoko TK, Khuri FR (2011) Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin 61:91–112. https://doi.org/10.3322/caac.20102 CrossRefPubMed

Remon J, Moran T, Majem M, Reguart N, Dalmau E, Marquez-Medina D, Lianes P (2014) Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins. Cancer Treat Rev 40:93–101. https://doi.org/10.1016/j.ctrv.2013.06.002 CrossRefPubMed

Rooney M, Devarakonda S, Govindan R (2013) Genomics of squamous cell lung cancer Oncologist 18:707–716. https://doi.org/10.1634/theoncologist.2013-0063 CrossRefPubMedPubMedCentral

Satow R et al (2010) Combined functional genome survey of therapeutic targets for hepatocellular carcinoma. Clin Cancer Res 16:2518–2528. https://doi.org/10.1158/1078-0432.ccr-09-2214 CrossRefPubMed

Scagliotti GV et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543–3551. https://doi.org/10.1200/jco.2007.15.0375 CrossRefPubMed

Schneider MA et al (2017) AURKA, DLGAP5, TPX2, KIF11 and CKAP5: Five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patients. Int J Oncol 50:365–372. https://doi.org/10.3892/ijo.2017.3834 CrossRefPubMedPubMedCentral

Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169–181. https://doi.org/10.1038/nrc2088 CrossRefPubMed

Shi YX, Yin JY, Shen Y, Zhang W, Zhou HH, Liu ZQ (2017) Genome-scale analysis identifies NEK2, DLGAP5 and ECT2 as promising diagnostic and prognostic biomarkers in human lung cancer. Sci Rep 7:8072. https://doi.org/10.1038/s41598-017-08615-5 CrossRefPubMedPubMedCentral

Shimo A, Nishidate T, Ohta T, Fukuda M, Nakamura Y, Katagiri T (2007) Elevated expression of protein regulator of cytokinesis 1, involved in the growth of breast cancer cells. Cancer Sci 98:174–181. https://doi.org/10.1111/j.1349-7006.2006.00381.x CrossRefPubMed

Siegel R et al (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62:220–241. https://doi.org/10.3322/caac.21149 CrossRefPubMed

Spigel DR et al (2011) Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol 29:2582–2589. https://doi.org/10.1200/jco.2010.30.7678 CrossRefPubMed

Sundar R, Soong R, Cho BC, Brahmer JR, Soo RA (2014) Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 85:101–109. https://doi.org/10.1016/j.lungcan.2014.05.005 CrossRefPubMed

Wang H et al (2004) Human Zwint-1 specifies localization of Zeste White 10 to kinetochores and is essential for mitotic checkpoint signaling. J Biol Chem 279:54590–54598. https://doi.org/10.1074/jbc.M407588200 CrossRefPubMed

Woo Seo D, Yeop You S, Chung WJ, Cho DH, Kim JS, Su Oh J (2015) Zwint-1 is required for spindle assembly checkpoint function and kinetochore-microtubule attachment during oocyte meiosis. Sci Rep 5:15431. https://doi.org/10.1038/srep15431 CrossRefPubMedPubMedCentral

Wu X et al (2017) Nucleolar and spindle associated protein 1 promotes the aggressiveness of astrocytoma by activating the Hedgehog signaling pathway. J Exp Clin Cancer Res 36:127. https://doi.org/10.1186/s13046-017-0597-y CrossRefPubMedPubMedCentral

Xie C et al (2011) KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases. Nucleic Acids Res 39:W316–W322. https://doi.org/10.1093/nar/gkr483 CrossRefPubMedPubMedCentral

Xu Z, Zhou Y, Cao Y, Dinh TL, Wan J, Zhao M (2016) Identification of candidate biomarkers and analysis of prognostic values in ovarian cancer by integrated bioinformatics analysis. Med Oncol 33:130. https://doi.org/10.1007/s12032-016-0840-y CrossRefPubMed

Zarogoulidis K et al (2013) Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a phase II randomized study. Drug Des Dev Ther 7:611–617. https://doi.org/10.2147/dddt.s43184 CrossRef

Title: ZWINT is the next potential target for lung cancer therapy
Authors: Fang Peng
Qiang Li
Shao-Qing Niu
Guo-Ping Shen
Ying Luo
Ming Chen
Yong Bao
Publication date: 01-03-2019
Publisher: Springer Berlin Heidelberg
Keywords: Lung Cancer
Lung Cancer
SCLC
Lung Cancer
SCLC
Published in: Journal of Cancer Research and Clinical Oncology / Issue 3/2019
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-018-2823-1

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2019

Radiomics-based machine learning methods for isocitrate dehydrogenase genotype prediction of diffuse gliomas

Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group

Effect of the botanical formula LCS101 on the anti-cancer effects of radiation therapy

TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database

Serum miR-16 as a potential biomarker for human cancer diagnosis: results from a large-scale population

PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage